ARTICLE | Translation in Brief
RNA BiTEs
BioNTech creates cancer bispecifics from mRNA.
June 29, 2017 10:54 PM UTC
BioNTech AG believes its RNA therapeutics platform can produce bispecific antibodies that circumvent the manufacturing and short plasma half-life problems of other technologies, and thinks its approach can accelerate the development timeline for bispecific T cell-engaging antibodies (BiTEs) in cancer.
In June, the company published a study in Nature Medicine demonstrating RNA injection could produce functional levels of a bispecific antibody in mice with a better PK profile and less frequent dosing than its recombinant equivalent. ...
BCIQ Company Profiles